Markets:

Overview

News

Currencies

International

Treasuries

RayzeBio, Inc. - Common Stock (NQ:RYZB)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 23, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about RayzeBio, Inc. - Common Stock

AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments ↗

March 19, 2024

AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...

Via Benzinga

The Best-Performing U.S. IPOs Of 2023 ↗

February 04, 2024

In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year.

Via Talk Markets

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace' ↗

January 05, 2024

Jim Cramer said WK Kellogg Co (NYSE: KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE: K)

Via Benzinga

Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio ↗

December 26, 2023

Via Benzinga

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗

December 29, 2023

The major indexes boast big annual gains with the Dow at record highs.

Via Investor's Business Daily

Topics Stocks

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned ↗

December 27, 2023

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...

Via Benzinga

Investor Sentiment Improves; Dow Jumps Over 150 Points ↗

December 27, 2023

The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.

Via Benzinga

Topics Stocks

Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher ↗

December 26, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The...

Via Benzinga

Topics Stocks

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 26, 2023

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 26, 2023

Via Benzinga

Stocks Extend Gains As Oil Prices Rise ↗

December 26, 2023

The short sprint to the end of 2023 is off to a good start, with the Dow Jones Industrial Average, S&P 500 Index, and Nasdaq Composite all sporting solid gains this afternoon.

Via Talk Markets

Topics Stocks

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% ↗

December 26, 2023

Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.

Via Investor's Business Daily

Why Is RayzeBio (RYZB) Stock Up 100% Today? ↗

December 26, 2023

RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.

Via InvestorPlace

Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals ↗

December 26, 2023

Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 26, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗

October 11, 2023

Via Benzinga

RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan ↗

October 10, 2023

JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗

October 10, 2023

Via Benzinga

Specialty Asian Grocer Maison Solutions Opens For Trading ↗

October 08, 2023

Following a couple of high-profile trading debuts, the IPO market slowed down again. There was only one public offering of note this week, with California-based specialty Asian grocer Maison Solutions...

Via Talk Markets

Topics Initial Public Offering

SoftBank-Owned Arm Jumps 20% In Market Debut ↗

September 17, 2023

British chip designer Arm made its public debut on Thursday, with the shares jumping 10% right as the stock opened for trading. Arm's was the most high-profile Nasdaq IPO in the last few years, with...

Via Talk Markets

Topics Initial Public Offering

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 ↗

October 06, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

On Tuesday, 386 stocks made new 52-week lows.

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.